Search results
Found 2776 matches for
The Oxford Vaccine Group is an independent multi-disciplinary clinical trials and epidemiology group based at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford. OVG works towards the goal of developing new and improved vaccines for the prevention of infection in adults and children.
Oxford leads first trial investigating dosing with alternating vaccines
4 February 2021
The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium
27 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
Oxford vaccine researchers talk research and home-schooling on ITV's This Morning
7 January 2021
Professor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.
Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
Oxford vaccine stimulates broad antibody and T cell functions
17 December 2020
Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
10 December 2020
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Philharmonic Orchestra film special tribute concert for the Oxford vaccine team
7 December 2020
A special concert to say thank you and pay tribute to the achievements of the Oxford vaccine team has been recorded at the Sheldonian Theatre for a film screening in time for Christmas
Oxford vaccine team shortlisted for parliamentary awards
24 November 2020
The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.
Oxford University breakthrough on global COVID-19 vaccine
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Award for OVG's learning games
19 November 2020
Learning games explaining the links between typhoid, sewage systems and food hygiene have won the gold prize at the Learning Technologies Awards 2020.
Oxford coronavirus vaccine produces strong immune response in older adults
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
SIMON Says…
14 November 2020
Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show
23 September 2020
Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
There is now clear data on Covid-19 and children: it should be safe to reopen English schools
18 August 2020
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Typhoid vaccine project wins Vice-Chancellor award
27 July 2020
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
New study reveals Oxford coronavirus vaccine produces strong immune response
20 July 2020
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
OVG study sheds light on coronavirus immunity in children
16 July 2020
First results of the What’s the STORY (Serum Testing Of Representative Youngsters) trial indicate higher resilience of children to COVID-19 compared to other respiratory illnesses.
Ebola vaccine approved for use by the European Commission
2 July 2020
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
Trial of Oxford COVID-19 vaccine in South Africa begins
1 July 2020
Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.